PL2637664T3 - Kompozycje i metody leczenia nadciśnienia płucnego - Google Patents

Kompozycje i metody leczenia nadciśnienia płucnego

Info

Publication number: PL2637664T3
Authority: PL; Poland
Prior art keywords: compositions; methods; pulmonary hypertension; treating pulmonary; treating
Prior art date: 2010-10-15

Application number

PL11833507T

Other languages

English (en)

Inventor

Luiz Belardinelli

Hunter Campbell Gillies

Faquan Liang

John Shryock

Suya Yang

Original Assignee

Gilead Sciences, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-15

Filing date

2011-10-14

Publication date

2017-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45939010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2637664(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-10-14 Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.

2017-09-29 Publication of PL2637664T3 publication Critical patent/PL2637664T3/pl

Links

239000000203 mixture Substances 0.000 title 1
208000002815 pulmonary hypertension Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL11833507T 2010-10-15 2011-10-14 Kompozycje i metody leczenia nadciśnienia płucnego PL2637664T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US39352910P	2010-10-15	2010-10-15
US201161490454P	2011-05-26	2011-05-26
US201161497475P	2011-06-15	2011-06-15

Publications (1)

Publication Number	Publication Date
PL2637664T3 true PL2637664T3 (pl)	2017-09-29

Family

ID=45939010

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11833507T PL2637664T3 (pl)	2010-10-15	2011-10-14	Kompozycje i metody leczenia nadciśnienia płucnego

Country Status (26)

Country	Link
US (3)	US20120269898A1 (pl)
EP (2)	EP3106163A1 (pl)
JP (2)	JP5806320B2 (pl)
KR (2)	KR20130069855A (pl)
CN (1)	CN103458690B (pl)
AR (1)	AR083422A1 (pl)
AU (2)	AU2011315891B2 (pl)
BR (1)	BR112013008983A2 (pl)
CA (1)	CA2814518C (pl)
CY (1)	CY1119007T1 (pl)
DK (1)	DK2637664T3 (pl)
EA (2)	EA201691759A1 (pl)
ES (1)	ES2627944T3 (pl)
HR (1)	HRP20170848T1 (pl)
HU (1)	HUE033346T2 (pl)
LT (1)	LT2637664T (pl)
MX (1)	MX346730B (pl)
NZ (2)	NZ610012A (pl)
PL (1)	PL2637664T3 (pl)
PT (1)	PT2637664T (pl)
RS (1)	RS56135B1 (pl)
SI (1)	SI2637664T1 (pl)
SM (1)	SMT201700297T1 (pl)
TW (1)	TWI542580B (pl)
WO (1)	WO2012051559A2 (pl)
ZA (1)	ZA201302746B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE025355T2 (en)	2006-12-12	2016-02-29	Gilead Sciences Inc	Composition for treating pulmonary hypertension
MX346730B (es)	2010-10-15	2017-03-30	Gilead Sciences Inc	Composiciones y metodos para el tratamiento de la hipertension pulmonar.
WO2014003678A1 (en) *	2012-06-28	2014-01-03	Xspray Microparticles Ab	Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014174529A2 (en) *	2013-04-23	2014-10-30	Hetero Research Foundation	Polymorphs of avanafil
WO2015069839A1 (en) *	2013-11-06	2015-05-14	Gilead Sciences, Inc.	Combination therapy for treating pulmonary hypertension
CN105581990A (zh) *	2014-08-27	2016-05-18	人福医药集团股份公司	安立生坦片剂及其制备方法
ES2933674T3 (es)	2015-03-13	2023-02-13	Univ Indiana Res & Tech Corp	Inhibidores de PDE5 para uso en la reducción del tamaño del quiste renal y/o prevención del crecimiento del quiste renal
DK3496739T3 (da)	2016-07-15	2021-05-10	Acceleron Pharma Inc	Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
CA3041679A1 (en) *	2016-10-27	2018-05-03	Lawrence S. ZISMAN	Combination therapy for treating pulmonary hypertension
WO2019010445A1 (en) *	2017-07-07	2019-01-10	The Regents Of The University Of Colorado, A Body Corporate	COMPOSITIONS AND METHOD FOR THE TREATMENT OF PULMONARY HYPERTENSION
EP3731870B1 (en)	2017-12-26	2025-11-12	Liqmeds Limited	Liquid oral formulations for pde v inhibitors
CN109406688A (zh) *	2018-09-28	2019-03-01	中国食品药品检定研究院	用于检测产品中违禁药品的标准样品
CA3158292A1 (en)	2019-11-29	2021-06-03	Alessandro MARESTA	Methods of treating pulmonary arterial hypertension
US11969424B2 (en)	2019-12-16	2024-04-30	Tenax Therapeutics, Inc.	Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
KR102606504B1 (ko) *	2020-04-10	2023-11-29	주식회사 대웅테라퓨틱스	니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
US20230174620A1 (en)	2020-04-28	2023-06-08	Acceleron Pharma Inc.	Actrii proteins and use in treating post-capillary pulmonary hypertension
CN112826944B (zh) *	2021-01-29	2023-08-15	台州职业技术学院	一种安立生坦包合物及其制备方法
US20250064799A1 (en)	2021-12-31	2025-02-27	Tenax Therapeutics, Inc.	Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
EP4684777A1 (en)	2024-07-24	2026-01-28	Adalvo Limited	A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino{1',2:1,6]pyrido[3,4-b]indole-1,4-dione

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US4326525A (en)	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US5364620A (en)	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US4902514A (en)	1988-07-21	1990-02-20	Alza Corporation	Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de)	1993-04-23	1994-10-27	Basf Ag	3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
DE19533023B4 (de)	1994-10-14	2007-05-16	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung
CA2395558C (en)	1997-11-12	2007-07-17	Bayer Aktiengesellschaft	Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6821975B1 (en)	1999-08-03	2004-11-23	Lilly Icos Llc	Beta-carboline drug products
EP1776108A1 (en)	2004-06-23	2007-04-25	Myogen, Inc.	Enoximone formulations and their use in the treatment of pde-iii mediated diseases
TW200621261A (en) *	2004-08-26	2006-07-01	Encysive Pharmaceuticals	Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US20060205733A1 (en)	2004-08-26	2006-09-14	Encysive Pharmaceuticals	Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
AU2007242555B2 (en)	2006-04-21	2010-12-16	Pfizer Products Inc.	Pyridine[3,4-b]pyrazinones
EP2091539A1 (en) *	2006-12-12	2009-08-26	Gilead Colorado, Inc.	Ambrisentan combined with a renin inhibitor for hypertensive disorder
HUE025355T2 (en)	2006-12-12	2016-02-29	Gilead Sciences Inc	Composition for treating pulmonary hypertension
CA2695259C (en)	2007-07-31	2016-05-24	Gilead Colorado, Inc.	Metabolites and derivatives of ambrisentan
WO2010062640A1 (en)	2008-10-28	2010-06-03	Gilead Colorado, Inc.	Methods for treating idiopathic pulmonary fibrosis and associated complications
MX346730B (es)	2010-10-15	2017-03-30	Gilead Sciences Inc	Composiciones y metodos para el tratamiento de la hipertension pulmonar.

2011
- 2011-10-14 MX MX2013004190A patent/MX346730B/es active IP Right Grant
- 2011-10-14 EP EP16180914.0A patent/EP3106163A1/en not_active Withdrawn
- 2011-10-14 PL PL11833507T patent/PL2637664T3/pl unknown
- 2011-10-14 DK DK11833507.4T patent/DK2637664T3/en active
- 2011-10-14 US US13/274,013 patent/US20120269898A1/en not_active Abandoned
- 2011-10-14 WO PCT/US2011/056404 patent/WO2012051559A2/en not_active Ceased
- 2011-10-14 LT LTEP11833507.4T patent/LT2637664T/lt unknown
- 2011-10-14 KR KR1020137012382A patent/KR20130069855A/ko not_active Ceased
- 2011-10-14 KR KR20147032816A patent/KR20150002876A/ko not_active Ceased
- 2011-10-14 RS RS20170640A patent/RS56135B1/sr unknown
- 2011-10-14 NZ NZ610012A patent/NZ610012A/en active IP Right Revival
- 2011-10-14 JP JP2013534043A patent/JP5806320B2/ja not_active Expired - Fee Related
- 2011-10-14 HU HUE11833507A patent/HUE033346T2/en unknown
- 2011-10-14 EP EP11833507.4A patent/EP2637664B1/en not_active Revoked
- 2011-10-14 EA EA201691759A patent/EA201691759A1/ru unknown
- 2011-10-14 HR HRP20170848TT patent/HRP20170848T1/hr unknown
- 2011-10-14 CA CA2814518A patent/CA2814518C/en not_active Expired - Fee Related
- 2011-10-14 PT PT118335074T patent/PT2637664T/pt unknown
- 2011-10-14 AU AU2011315891A patent/AU2011315891B2/en active Active
- 2011-10-14 EA EA201390428A patent/EA026074B1/ru active IP Right Revival
- 2011-10-14 CN CN201180060879.3A patent/CN103458690B/zh not_active Expired - Fee Related
- 2011-10-14 ES ES11833507.4T patent/ES2627944T3/es active Active
- 2011-10-14 SM SM20170297T patent/SMT201700297T1/it unknown
- 2011-10-14 BR BR112013008983A patent/BR112013008983A2/pt not_active IP Right Cessation
- 2011-10-14 NZ NZ707213A patent/NZ707213A/en active IP Right Revival
- 2011-10-14 SI SI201131190A patent/SI2637664T1/sl unknown
- 2011-10-14 TW TW100137481A patent/TWI542580B/zh not_active IP Right Cessation
- 2011-10-17 AR ARP110103833A patent/AR083422A1/es unknown
2013
- 2013-04-17 ZA ZA2013/02746A patent/ZA201302746B/en unknown
- 2013-11-13 US US14/079,548 patent/US9549926B2/en active Active
2015
- 2015-06-10 JP JP2015117196A patent/JP2015178528A/ja not_active Withdrawn
2016
- 2016-07-04 AU AU2016204638A patent/AU2016204638B2/en not_active Ceased
- 2016-08-09 US US15/232,570 patent/US20160346280A1/en not_active Abandoned
2017
- 2017-06-22 CY CY20171100660T patent/CY1119007T1/el unknown

Also Published As

Publication number	Publication date
US9549926B2 (en)	2017-01-24
RS56135B1 (sr)	2017-10-31
JP2014506870A (ja)	2014-03-20
EP2637664A4 (en)	2014-09-10
ES2627944T3 (es)	2017-08-01
HUE033346T2 (en)	2017-11-28
CY1119007T1 (el)	2018-01-10
US20160346280A1 (en)	2016-12-01
PT2637664T (pt)	2017-06-22
ZA201302746B (en)	2014-06-25
SI2637664T1 (sl)	2017-07-31
EA201691759A1 (ru)	2017-05-31
WO2012051559A3 (en)	2013-10-17
AU2016204638B2 (en)	2018-06-07
HRP20170848T1 (hr)	2017-08-25
JP2015178528A (ja)	2015-10-08
US20140275098A1 (en)	2014-09-18
CA2814518C (en)	2016-09-20
CA2814518A1 (en)	2012-04-19
CN103458690A (zh)	2013-12-18
EP2637664A2 (en)	2013-09-18
SMT201700297T1 (it)	2017-07-18
LT2637664T (lt)	2017-11-10
MX2013004190A (es)	2013-07-29
EP2637664B1 (en)	2017-03-29
US20120269898A1 (en)	2012-10-25
NZ707213A (en)	2016-12-23
WO2012051559A2 (en)	2012-04-19
TW201219372A (en)	2012-05-16
DK2637664T3 (en)	2017-06-19
JP5806320B2 (ja)	2015-11-10
EA026074B1 (ru)	2017-02-28
KR20150002876A (ko)	2015-01-07
AU2011315891A1 (en)	2013-05-23
EA201390428A1 (ru)	2014-02-28
KR20130069855A (ko)	2013-06-26
NZ610012A (en)	2015-05-29
TWI542580B (zh)	2016-07-21
BR112013008983A2 (pt)	2016-07-05
EP3106163A1 (en)	2016-12-21
AU2016204638A1 (en)	2016-08-04
AU2011315891B2 (en)	2015-08-13
CN103458690B (zh)	2016-03-16
MX346730B (es)	2017-03-30
AR083422A1 (es)	2013-02-21

Publication	Publication Date	Title
ZA201302746B (en)	2014-06-25	Compositions and methods of treating pulmonary hypertension
IL250824B (en)	2019-03-31	Certain amino-pyrimidines, their assemblies, and methods of using them
IL254909A0 (en)	2017-12-31	Preparations and methods for treating edible material and their substrates
EP2534205A4 (en)	2014-11-05	RHEOLOGY MODIFIER COMPOSITIONS AND METHODS OF USE
IL232977B (en)	2019-01-31	Intra-episode dexmedetomidine preparations and methods of using them
EP2675471A4 (en)	2015-01-28	HSA-RELATED COMPOSITIONS AND USE PROCESSES
IL222291A0 (en)	2012-12-31	Compositions and methods of synthesis of pyridinoylpiperidine
EP2655334A4 (en)	2014-12-31	COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
EP2633046A4 (en)	2015-05-06	COMPOSITIONS AND METHODS FOR INHIBITING PCSK9 GENES
IL225672A0 (en)	2013-06-27	Methods and compositions for polymerase inhibition
EP2593571A4 (en)	2015-09-30	SWEETENER COMPOSITIONS AND METHODS OF PRODUCING THE SAME
EP2523944A4 (en)	2013-06-19	COMPOUNDS AND COMPOSITIONS FOR IMPROVING COGNITION, METHODS OF MAKING THE SAME, AND METHODS OF TREATMENT
EP2771030A4 (en)	2015-07-22	COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
EP2576579A4 (en)	2014-08-13	COMPOSITIONS AND METHODS FOR TREATING HEPATIC FIBROSIS
SG10201500165RA (en)	2015-03-30	Abradable composition and method of manufacture
IL225488A0 (en)	2013-06-27	Compounds and methods for the treatment of hematological malignancies
EP2622029A4 (en)	2014-06-04	PRINTING COLORING COMPOSITIONS AND METHOD FOR THEIR USE
IL220715A0 (en)	2012-08-30	Nutritive compositions and methods of using same
EP2590674A4 (en)	2014-09-10	COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
WO2011137427A9 (en)	2012-04-12	Compositions and methods for treating pulmonary conditions
IL253853A0 (en)	2017-09-28	Methods and preparations for the treatment or prevention of symptoms of hormonal changes
EP2566485A4 (en)	2014-03-12	IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF
GB201018650D0 (en)	2010-12-22	Methods and compositions
EP2672968A4 (en)	2016-07-13	ECONAZOL COMPOSITION AND TREATMENT PROCEDURE THEREWITH
EP2563923A4 (en)	2014-12-17	COMPOSITIONS AND METHODS FOR REDUCING SCARS AND TREATING FIBROSIS